Abstract A series of 7-chloro-4-[4-(substituted arylideneimino)] 2,5-dioxo-1,4 piperazinoquinoline VI was designed by molecular hybridization approach and synthesized for biological evaluation. Virtual screening was carried out through docking the designed compounds into the ATP binding site of epidermal growth factor receptor (EGFR) to predict if these compounds have similar binding mode as the EGFR inhibitors. Subsequently, the compounds were examined for their cytotoxic effect on human breast cell-line (MCF-7) in which the EGFR is highly expressed. Although most of the compounds were quite effective on the breast cancer cell line examined, the compounds II, III, IVa, IVc, VIa, VIc emerged as the most active among the prepared series. Thus 7-chloro-4-[4-(substitutedarylideneimino) 2,5-dioxo-1,4 piperazinoquinoline can serve as the prototype molecule for further development of a new class of EGFR Tyrosine Kinase inhibitors and anti-breast cancer agents. 
Introduction
The growing incidence of drug resistance to cancer chemotherapeutic agents represents a serious medical problem. 1 Therefore there is an urgent need to develop new classes of chemotherapeutic agents to treat cancer. 2 A combinational chemotherapeutic drug with different mechanisms of action is one of the methods that are being adopted to treat cancer. [3] [4] [5] [6] Besides the exploitation of new targets, there is another approach combining two or more pharmacophores into a single molecule. Therefore a single molecule containing more than one pharmacophore, each with different mode of action, could be beneficial for the treatment of cancer. [7] [8] [9] These merged pharmacophores may be addressing the active site of different targets and offer the possibility to overcome drug resistance. In addition, this approach can also reduce unwanted side effects. 3, 4, 6, 7 The success of this hybridization approach has already been applied in developing novel antibacterial and antimalarial agents to overcome drug resistance. [9] [10] [11] [12] [13] Recently it has been demonstrated that 10 lM chloroquine ( Fig. 1 CQ) significantly increases cancer cell killing effects. 3, 4, 14 Although the antineoplastic activity of these quinolines was attributed to intercalating binding to DNA, there were additional advantages in quinolines that interact with DNA, with low association constant. The corresponding significant increase in the amount of free drug at equilibrium may have an important effect upon distribution and hence the spectrum of activity and accessibility of these molecules to solid tumor. 15, 16 In addition a number of quinoline derivatives were reported to reverse tumor cell multidrug resistance. 17, 18 Several CQ analogs (Figs. 1-3 ) have been synthesized and examined as cytotoxic agents against (MCF-7) breast cancer cell line. Some of these compounds were very effective. 19 The lysosomotropic CQ accumulated in the lysosomes, raises intra-lysosomal pH, and interferes with auto-phagosome degradation in the lysosomes. This unique property of CQ and its analogs may be important for the enhancement of cell killing by cancer therapeutic agents in a variety of different tumors. 20 Published data showed that the piperazinoquinoline pharmacophore is one of the most effective newly emerging class of heterocyclic molecules that possessed antitumor activity 21, 22 (Figs. 2, 4 and 5). In addition many researches proved the importance of azomethine link or Schiff bases in anticancer drug.
23,24
The present work is an effort toward developing effective anticancer agents by a hybrid pharmacophore approach using the 4-piperazinyl-quinoline scaffold. There are accumulating lines of evidence that hybridization of two or more bioactive molecules with complementary pharmacophoric functions or with different mechanisms of action often render synergistic effects. [8] [9] [10] [11] [12] [13] Encouraged by these previous reports we designed different set of compounds (Scheme 1) by hybridizing two or more different pharmacophores (7-chloroquinolines, azomethine, piperazinedione) in the aim of prospecting their antibreast cancer potentiality.
Chemistry
Compounds (II-VI) described in this study were synthesized as outlined in Scheme 1. 4,7-Dichloroquinoline I was reacted with glycine ethyl ester to afford compound II which upon reaction with hydrazine hydrate produced the key compound III. The target compounds VIa-e were obtained through two different pathways. The first includes the reaction of compound III with different aromatic aldehydes to yield Shiff's base IVa-f which upon cyclization with chloroacetylchloride afforded the desired compounds VIa-e. Alternatively, the second pathway involves primarily cyclization of the key compound III via reaction with chloroacetylchloride to produce compound V which through interaction with different aromatic aldehydes ends into our target compounds.
Materials and methods

Experimental
Melting points were determined with a Gallenkamp (London, UK) melting point apparatus and are uncorrected. IR spectra (KBr, cm À1 ) were recorded on Bruker Vector, 22 FT-IR (Fourier Transform Infrared -FT-IR) (Germany) spectrometer. 1 H NMR spectra were recorded on a Varian Gemini-200 (200-MHz, Foster City Calif., USA) and Varian Mercury-300 (300-MHz, City: Palo Alto, State: Calif., USA spectrometers using dimethyl sulfoxide (DMSO)-d 6 as a solvent and tetramethylsilane (TMS) as an internal standard (Chemical shift in d, ppm). Mass spectra were determined using Mass spectrometers GC/MS Shimadzu QP 1000 EX (Shimadzu Corporation, Tokyo, Japan) with ionization energy 70 eV. Elemental analyses were determined using Automatic Elemental Analyzer CHN Model 2400 Perkin-Elmer (USA) at Microanalytical Center, Faculty of Science, Cairo University, Egypt. All the results of elemental analyses corresponded to the calculated values within experimental error. Progress of the reaction was monitored by thin-layer chromatography (TLC) using precoated TLC sheets with Ultraviolet (UV) fluorescent silica gel (Merck 60F254) and spots were visualized by iodine vapors or irradiation with UV light (254 nm). All the chemicals were purchased from Sigma-Aldrich.
7-Chloro-4-ethoxycarbonylmethylene aminoquinoline (II)
A mixture of glycine ethyl ester (0.01 mol) and 4,7-dichloroquinoline I (0.01 mol) in absolute ethanol (10 ml) containing few drops of HCl was refluxed for 2 h to give a creamy white precipitate which was filtered, washed with cold aqueous alcohol and recrystallized from absolute alcohol. Yield: 80%; mp: 185-187°C; IR: 3300-1610 cm 
7-Chloro-4-hydrazinocarbonylmethylene aminoquinoline (III)
A mixture of (0.01 mol) of II and hydrazine hydrate (0.03 mol) was refluxed in absolute ethanol (10 ml) for 2 h. The solvent was evaporated under vacuum; the resulting oil was triturated with ice. The buff precipitate formed, was filtered, washed with alcohol/water and crystallized from ethanol. A mixture of III (0.01 mol) and the appropriate aldehyde (0.01 mol) in absolute ethanol and drops of glacial acetic acid was refluxed for 3 h. The precipitate formed was filtered off, washed with alcohol dried and recrystallized from DMF/water. 
General procedure for the preparation of 7-chloro-4-[4-(substituted arylidene imino)] 2,5-dioxo-1-4 piperazinoquinoline (VIa-f)
Method A: Compounds IVa-f (0.1 mol) were refluxed with chloroacetylchloride (10 ml) in absolute ethanol (10 ml) for 4 h. The refluxed mixture was poured into ice/water to produce compounds VIa-f.
Method B: A mixture of compound V (0.1 mol) and the appropriate aromatic aldehyde in absolute ethanol (10 ml) containing few drops of glacial acetic acid was refluxed for 4 h. The solid product was filtered off and recrystallized from DMF/water. 
In vitro cytotoxicity
Since breast cells are known to over express EGFR, which leads to continuous activation of the EGFR pathway involved in cell proliferation, therefore all the compounds synthesized were evaluated for their cytotoxicity on breast cancer cell line MCF-7 using the sulfo-Rho-damine-B stain (SRB) assay using the method of skehan. 25 Cells were plated in 96-multiwall microtiter plate (10 4 cells/ well) for 24 h before treatment with the compound(s) to allow attachment of cell to the wall of the plate. Test compounds were dissolved in DMSO and diluted with saline to the appropriate volumes. Different concentration of the compound under test (0.1, 2.5, 5 and 10 lg/ml) were added to the cell monolayer. Triplicate wells were prepared for each individual dose. Monolayer cells were incubated with the compound(s) for 48 h at 37°C and in atmosphere of 5% CO 2 . After 48 h, cells were fixed, washed and stained for 30 min with 0.4% (wt/vol) with SRB dissolved in 1% acetic acid unbound dye was removed by four washes with 1% acetic acid and attached slain was recovered with Tris EDTA buffer. Color intensity was measured in an ELISA reader. The relation between surviving fraction and drug concentration is plotted to get the survival curve. Most of the tested compounds exhibited potent inhibitory activity against MCF-7 cell line (Table 1 and Figs. 3-6 ).
Molecular modeling study
Docking study was carried out for the target compounds into EGFR using SYBYL version 7.3. Tripos Inc. with malegro virtual docker program version 2007. The crystal structure of the enzyme and lapatinib (1XKK) was obtained from protein data bank PDB 26 since it was found that lapatinib mimic ATP and bind to the ATP binding region of the kinase active site. Therefore our compounds were modeled by positioning them in the lapatinib binding site in accordance with the published crystal structures of quinazoline derivatives bound to kinase. 21, 27 The entire complex was then subjected to alternate cycles of minimization and dynamics, the intent was to get a satisfactory structure for the complex that was consistent with the published crystal structure. 28, 29 From the comparative docking study of our compounds with many structurally related lead compounds, such as lapatinib and gefitinib, we could observe how our compounds might bind to the kinase binding site. Based on a knowledge of the structure of similar active sites, we docked lapatinib into the active site of the enzyme (Fig. 7) . Docking studies have revealed that lapatinib ring binds to a narrow hydrophobic pocket in the EGFR-TK domain with three hydrogen bond interaction with amino acids in vicinity while the aniline moiety lies in a deep and hydrophobic pocket. The bulky sulfamoyl group at C-4 of aniline moiety lies at the same position of the 3 0 -chloro-4 0 -(3-fluorobenzyloxy) moiety of lapatinib with total interaction energy equal to À71 kcal/mol and RMSD equal to 0.004 indicating that the ligand was chosen to interact with the enzyme at the same sites as the main li- (Fig. 8) . Compound VIc was also docked in the ATP binding site of EGFR-TK with total interaction energy equal to À66.3 kcal/mol and showing two hydrogen bond with R 841&C 797 (Fig. 9) . We can observe that the quinoline ring lies in a deep and hydrophobic pocket in the EGFR as in case of the chosen lead compounds with total interaction energy nearly approaching that of the lead compound lapatinib.
Results and discussion
The biological screening results (Table 1) revealed that cytotoxic activities increase following the conversion of the ester II to the corresponding acid hydrazide III with IC 50 values equal to 3.09 and 2.84 lM, respectively. Converting the acid hydrazide III to the corresponding arylidene derivatives reduces the cytotoxic activities as seen from compounds IVa and IVc where IC 50 were 5.37 and 8.83 lM, respectively. Unfortunately cyclization of compound III to produce compound V abolishes the activity, which was restored again as seen from compound VIa and VIc with IC 50 1.41 and 2.75 lM, respectively; a result that supports our hypothesis of designing a hybrid compound bearing three cytotoxic pharmacophore; herein: 7-chloroquinoline, a piperazine moiety and an azomethine group. It is also clear from the obtained data that electronic effect of the substituent in the para position of the arylidene group in the series comprising compounds VIa-e, seems to be an important determinant of activity since the bromo derivative VIa was more active than its methoxy congenere VIc (IC 50 equal to 1.41 and 2.75 lM, respectively). These results indicate a parallel correlation between molecular modeling study and measurement of potential cytotoxicity as shown in compounds IVc and VIc with total interaction energy equal to À65.3 and À66.3 while IC 50 equals 8.83 and 2.75, respectively. We can conclude that the results obtained potentiate the hypothesis of hybrid pharmacophore (compare compounds IVc and VIc).
These preliminary encouraging results of biological screening of the tested compounds could offer a new pharmacophore in this field that may lead to discovery of a potent antitumor agent. 
